- Home
- BYD vs AXSM Comparison
BYD vs AXSM Comparison
Compare BYD & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYD
- AXSM
- Stock Information
- Founded
- BYD 1973
- AXSM 2012
- Country
- BYD United States
- AXSM United States
- Employees
- BYD N/A
- AXSM N/A
- Industry
- BYD Hotels/Resorts
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- BYD Consumer Discretionary
- AXSM Health Care
- Exchange
- BYD Nasdaq
- AXSM Nasdaq
- Market Cap
- BYD 6.8B
- AXSM 5.9B
- IPO Year
- BYD 1993
- AXSM 2015
- Fundamental
- Price
- BYD $86.48
- AXSM $120.30
- Analyst Decision
- BYD Buy
- AXSM Strong Buy
- Analyst Count
- BYD 13
- AXSM 19
- Target Price
- BYD $87.25
- AXSM $174.26
- AVG Volume (30 Days)
- BYD 785.7K
- AXSM 516.8K
- Earning Date
- BYD 10-23-2025
- AXSM 11-11-2025
- Dividend Yield
- BYD 0.83%
- AXSM N/A
- EPS Growth
- BYD 26.05
- AXSM N/A
- EPS
- BYD 6.48
- AXSM N/A
- Revenue
- BYD $4,027,724,000.00
- AXSM $495,033,000.00
- Revenue This Year
- BYD N/A
- AXSM $63.62
- Revenue Next Year
- BYD N/A
- AXSM $55.72
- P/E Ratio
- BYD $13.34
- AXSM N/A
- Revenue Growth
- BYD 6.40
- AXSM 69.83
- 52 Week Low
- BYD $58.94
- AXSM $75.56
- 52 Week High
- BYD $88.49
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- BYD 56.91
- AXSM 54.51
- Support Level
- BYD $85.56
- AXSM $117.60
- Resistance Level
- BYD $88.49
- AXSM $124.53
- Average True Range (ATR)
- BYD 1.72
- AXSM 3.51
- MACD
- BYD 0.25
- AXSM -0.13
- Stochastic Oscillator
- BYD 74.10
- AXSM 63.63
About BYD Boyd Gaming Corporation
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. Midwest and South hold the key number of entertainment properties, and it generate the majority of sales for the company.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.